[Translation] A multicenter, open-label, phase Ib/II clinical trial evaluating BEBT-908 and BEBT-109 alone or in combination in advanced non-small cell lung cancer
主要目的:
1.评价BEBT-908与BEBT-109单药或联合治疗晚期非小细胞肺癌的有效性;
2.评价BEBT-908与BEBT-109单药或联合治疗晚期非小细胞肺癌的安全性和耐受性。
次要目的:
1.评价BEBT-908与BEBT-109单药或联合治疗晚期非小细胞肺癌的生物标志物药效学意义;
2.评价BEBT-908与BEBT-109单药或联合治疗晚期非小细胞肺癌的药代动力学特征。
[Translation] main purpose:
1. To evaluate the efficacy of BEBT-908 and BEBT-109 alone or in combination in the treatment of advanced non-small cell lung cancer;
2. To evaluate the safety and tolerability of BEBT-908 and BEBT-109 alone or in combination in the treatment of advanced non-small cell lung cancer.
Secondary purpose:
1. To evaluate the biomarker pharmacodynamics significance of BEBT-908 and BEBT-109 alone or in combination in the treatment of advanced non-small cell lung cancer;
2. To evaluate the pharmacokinetics of BEBT-908 and BEBT-109 alone or in combination in the treatment of advanced non-small cell lung cancer.